Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for metabolic disorders, particularly type 2 diabetes and obesity. At the heart of this shift is the explosive rise of GLP-1 receptor agonists, once a niche therapeutic class, now a multi-billion-dollar market shaping the future of chronic disease management. With this surge in clinical and commercial success, the GLP-1 technology space has become a hotbed for mergers and acquisitions (M&A), as major pharma players race to secure their foothold in what many consider the next blockbuster category.
Read the full article: GLP-1 Receptor Agonists: The Surge of M&A Activity and the Future of Metabolic Health //
Source: https://www.foley.com/insights/publications/2025/06/glp-1-receptor-agonists-m-a-activity-future-metabolic-health/